Background: In the field of nuclear medicine, radiopharmaceuticals play a great role in enhancing the diagnostic capabilities as well as delivering specific treatments. It is crucial to comprehend how and to what extent their roles change and how well they perform their tasks so that improvements in the quality of patients’ care and the efficiency of treatment can be made. Aim: The study is an attempt to review radiopharmaceuticals in diagnostic imaging and treatment based on the current literature available. Method: Accordingly, to exercise the methodology of a systematic review, the PRISMA 2020 guidelines were adopted. The search of 12 databases provided 1067 items; other sources gave 15 leads, for a total of 1082 records. Thus, from 75 duplicates removed and 1,010 screened, there were 935 studies ultimately included or excluded in the meta-analysis. Using the inclusion criteria, this number was first brought down to 961 records, and 49 of them moved to the next level of evaluations. From these, 31 were eliminated due to methodological problems, the subject, for being proposal, or the language not being English. Beside, after consideration of 18 full-text quantitative articles, 8
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً